Ifosfamide

Alkylating Agent
DB01181
Approved Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy

1 Targets
0 Resistance Mutations
10 References
3D Structure No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action

The exact mechanism of ifosfamide has not been determined, but appears to be similar to other alkylating agents. Ifosfamide requires biotransformation in the liver by mixed-function oxidases (cytochrome P450 system) before it becomes active. After metabolic activation, active metabolites of ifosfamide alkylate or bind with many intracellular molecular structures, including nucleic acids. The cytotoxic action is primarily through the alkylation of DNA, done by attaching the N-7 position of guanine to its reactive electrophilic groups. The formation of inter and intra strand cross-links in the DNA results in cell death.

Details
DrugBank ID DB01181 ↗
Approval Date 1988-12-30
Molecular Weight 261.086 g/mol
Drug Class Alkylating Agent
ATC Codes L01AA06
Synonyms Ifosfamida, Ifosfamidum, Iphosphamide
SMILES
ClCCNP1(=O)OCCCN1CCCl
ADMET Profile
Computing properties…